Market Place
Sourcing Support
Peptilogics Reports +ve 90-Day Top Line Data From Ph1b Trial of PLG0206
24 May 2023 //
BUSINESSWIRE
Peptilogics Completes Phase 1b Trial Enrollment Data of PLG0206
06 Apr 2023 //
BUSINESSWIRE
Peptilogics Hosting Discussion with Experts on High Unmet Medical Need
21 Feb 2023 //
BUSINESSWIRE
Peptilogics doses first subject in periprosthetic joint infection trial
07 Oct 2022 //
CLINICALTRIALSARENA
Peptilogics Presents Data of Engineered Peptide PLG0206 at the 2022 ASM/ESCMID
07 Oct 2022 //
BUSINESSWIRE
Peptilogics Announces First Patient Dosed in Phase 1b Study of PLG0206
06 Oct 2022 //
BUSINESSWIRE
EpiAxis Therapeutic, Peptilogics enter strategic drug discovery partnership
17 Aug 2022 //
BIOSPECTRUMASIA
EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership
15 Aug 2022 //
BUSINESSWIRE
Peptilogics Strengthens Leadership Team with Executive Appointments
10 Aug 2022 //
BUSINESSWIRE
Peptilogics to Participate in MSIS 32nd Annual Open Scientific Meeting
02 Aug 2022 //
BUSINESSWIRE
Peptilogics Receives FDA FTD for PLG0206 for Periprosthetic Joint Infection
19 Jul 2022 //
BUSINESSWIRE
Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration
12 Jul 2022 //
BUSINESSWIRE
Peptilogics to Present Data Highlighting Designed Antimicrobial Peptide
19 Apr 2022 //
BUSINESSWIRE
Peptilogics’ Presentations at AAOS 2022 Annual Meeting on PLG0206 for PJI
22 Mar 2022 //
BUSINESSWIRE
FDA Clears IND Application for Peptilogics` PLG0206
10 Jan 2022 //
BUSINESSWIRE
Peptilogics Receives Award from Cystic Fibrosis Foundation for PLG0301 & PLG0206
05 Jan 2022 //
BUSINESSWIRE
Peptilogics Announces 2 Peer-Reviewed Publications on PLG0206
01 Dec 2021 //
BUSINESSWIRE
Peptilogics to Present Phase 1 Clinical Data of PLG0206 at IDWeek 2021
22 Sep 2021 //
BUSINESSWIRE
Peptilogics and Cerebras Systems Partner on AI Solution for Peptide Therapeutics
18 Aug 2021 //
BUSINESSWIRE
Peptilogics Announces Successful Completion of Phase 1 Clinical Trial of PLG0206
13 Apr 2021 //
PRNEWSWIRE
Peptilogics Closes $35.4 Million Series B Financing to Further Proprietary
22 Dec 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.